Publications by authors named "Igor Astaturov"
Although histological and molecular classifications have been extensively studied for gastric cancer (GC), targeted therapies for GC remain limited. CDH1 mutations (MT) are characteristic of genomically stable GC and are associated with poor prognosis, but lack effective or targeted therapies. Here, we showed the overall mutation frequency of CDH1 was 9.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess the safety and effectiveness of combining quinacrine with capecitabine in treating patients with metastatic colorectal cancer (mCRC) who had not responded to previous treatments.
- The trial established a maximum tolerated dose of quinacrine as 100 mg twice daily, with manageable side effects, while also noting 5 patients showed stable disease outcomes.
- Although the expansion phase was stopped early due to manufacturing issues, the treatment regimen indicated a median time to tumor progression of 2.12 months and median overall survival of 5.22 months, suggesting potential benefits for heavily treated mCRC patients.